Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

AlphaRx Receives SFDA Approval for Topical Arthritis Product

publication date: Dec 7, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

AlphaRx received approval from the State FDA of China for Indaflex™, a topical arthritis relief product. Indaflex™ is a topical formulation of Indomethacin that is incorporated in a nanotechnology drug delivery system developed by AlphaRx. Previously, Indaflex™ was approved in Mexico. AlphaRx International Holdings (AIH), the Hong Kong affiliate of AlphaRx, will launch Indaflex™ in 2008, and it is already building a plant in China to produce the drug. More details....

Stock Symbols: (OTCBB:ALRX) (NYSE: MRK)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners